NVP-2203 is under clinical development by NVP Healthcare and currently in Phase III for Hypercholesterolemia. According to GlobalData, Phase III drugs for Hypercholesterolemia have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how NVP-2203’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NVP-2203 is under development for the treatment of primary hypercholesterolemia and dyslipidemia. It is administered through oral route as tablets.
NVP Healthcare overview
NVP Healthcare formerly Navipharm, develops novel pharmaceuticals products and microbiomes. NVP Healthcare is headquartered Suwon, Gyeonggi, South Korea.
For a complete picture of NVP-2203’s drug-specific PTSR and LoA scores, buy the report here.